Which biotechnology company's CEO was convicted of insider trading in 2003?

Which biotechnology company's CEO was convicted of insider trading in 2003? ImClone Systems. Its chief executive, Samuel D. Waksal, became the central figure in the ImClone stock-trading scandal.

Waksal learned that the U.S. Food and Drug Administration had rejected Erbitux, an experimental cancer drug that ImClone developed with Bristol-Myers Squibb. Before the news became public, he tried to sell ImClone shares and urged family members to do the same. The FDA decision caused the stock to plunge when announced in December 2001.

Waksal was arrested in 2002 and pleaded guilty to securities fraud, bank fraud, and other charges. On June 10, 2003, he was sentenced to seven years and three months in prison and ordered to pay more than $4 million in fines and back taxes. The case also drew attention because Martha Stewart sold ImClone stock after receiving a tip from her broker, though her conviction involved obstruction and making false statements rather than insider trading.

A common mix-up is naming Waksal rather than the company. The question asks which biotechnology company employed the convicted CEO, so ImClone Systems is the canonical answer.